FDA Regulation of Peptides: What You Need to Know

Peptide regulation in the United States is complex and evolving. The regulatory status of any given peptide depends on whether it has been approved by the FDA as a drug, whether it is classified as a dietary supplement, and whether compounding pharmacies are permitted to produce it.

Understanding these distinctions matters because the legal status of a peptide directly affects access, quality control, and the reliability of information available about it. This guide covers the current regulatory framework as of March 2026.

Several peptides have completed the full FDA approval process, meaning they have demonstrated safety and efficacy through rigorous clinical trials and are legally available by prescription:

Semaglutide is approved as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral formulation for type 2 diabetes. Tirzepatide is approved as Mounjaro for type 2 diabetes and Zepbound for weight management. Bremelanotide (PT-141) is approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Tesamorelin is approved as Egrifta for HIV-associated lipodystrophy.

These compounds have established safety profiles, standardized manufacturing, and clear clinical indications. They represent the gold standard of evidence in the peptide space.

In late 2023, the FDA placed several popular research peptides on the "Category 2" list — a classification that prohibits compounding pharmacies from producing these substances for human use under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Peptides placed on Category 2 include: BPC-157, TB-500 (Thymosin Beta-4), AOD-9604, CJC-1295, GHK-Cu, Ipamorelin, Kisspeptin-10, Selank, Semax, and several others.

The FDA's reasoning: The agency cited three primary concerns: potential immune reactions (immunogenicity), manufacturing impurities in bulk peptide production, and insufficient human safety data. The FDA argued that without adequate safety evidence, these compounds should not be compounded for patient use.

The counter-arguments: Physician groups, compounding pharmacies, and patient advocacy organizations have pushed back strongly. Their arguments include: these compounds have been used clinically for years with acceptable safety profiles in practice; the FDA's process for evaluating bulk drug substances was inadequate; banning compounding forces patients to obtain peptides from unregulated sources, which is less safe; and some of these compounds (like Thymosin Alpha-1) have regulatory approval in other countries.

Ongoing legal challenges: Several lawsuits and legal challenges are active. The Outsourcing Facilities Association and individual compounding pharmacies have challenged the Category 2 classifications through administrative and legal channels.

Many peptides are sold as "research chemicals" or "for research purposes only." This designation means the compound is not approved for human use and is theoretically sold only for laboratory research.

In practice, many consumers purchase research peptides intending to use them personally. This exists in a regulatory gray area — the sale of research chemicals is not inherently illegal, but marketing them for human consumption or therapeutic use is. The FDA has the authority to take enforcement action against vendors that explicitly or implicitly market research peptides for human use.

The research chemical market has significant quality control concerns. Unlike FDA-approved drugs, research peptides are not subject to Good Manufacturing Practice (GMP) requirements. Purity, sterility, and accurate labeling vary significantly between vendors. Third-party certificates of analysis (COAs) with HPLC purity testing are the primary quality indicator consumers use, but these can be fabricated or outdated.

The World Anti-Doping Agency (WADA) maintains a separate regulatory framework for athletes. Many peptides are explicitly prohibited under the WADA Prohibited List:

Section S0 (Non-Approved Substances) prohibits all pharmacological substances not addressed by other sections and not approved for human therapeutic use. This captures most research peptides including BPC-157 (explicitly listed as an example since 2022), TB-500, CJC-1295, and Ipamorelin.

Section S2 (Peptide Hormones, Growth Factors) prohibits growth hormone secretagogues, GH-releasing peptides, and related compounds.

Athletes under WADA jurisdiction — including Olympic athletes, NCAA athletes, and athletes in most professional leagues — face sanctions ranging from warnings to multi-year bans for positive tests involving prohibited peptides. There is generally no basis for a Therapeutic Use Exemption (TUE) for non-approved peptides.